Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 9/2017

01-09-2017 | Invited Review

Gaseous Mediators in Gastrointestinal Mucosal Defense and Injury

Authors: John L. Wallace, Angela Ianaro, Gilberto de Nucci

Published in: Digestive Diseases and Sciences | Issue 9/2017

Login to get access

Abstract

Of the numerous gaseous substances that can act as signaling molecules, the best characterized are nitric oxide, carbon monoxide and hydrogen sulfide. Contributions of each of these low molecular weight substances, alone or in combination, to maintenance of gastrointestinal mucosal integrity have been established. There is considerable overlap in the actions of these gases in modulating mucosal defense and responses to injury, and in some instances they act in a cooperative manner. Each also play important roles in regulating inflammatory and repair processes throughout the gastrointestinal tract. In recent years, significant progress has been made in the development of novel anti-inflammatory and cytoprotective drugs that exploit the beneficial activities of one or more of these gaseous mediators.
Literature
1.
Wallace JL. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn’t the stomach digest itself? Physiol Rev. 2008;88:1547–1565.CrossRefPubMed
2.
Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109–142.PubMed
3.
Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci. 1996;16:1066–1071.PubMed
4.
5.
6.
Wallace JL, Wang R. Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. Nat Rev Drug Discov. 2015;14:329–345.CrossRefPubMed
7.
Olson KR, Straub KD. The role of hydrogen sulfide in evolution and the evolution of hydrogen sulfide in metabolism and signaling. Physiology. 2016;31:60–72.CrossRefPubMed
8.
Goubern M, Andriamihaja M, Nübel T, Blachier F, Bouillaud F. Sulfide, the first inorganic substrate for human cells. FASEB J. 2007;21:1699–1706.CrossRefPubMed
9.
Mimoun S, Andriamihaja M, Chaumontet C, et al. Detoxification of H2S by differentiated colonic epithelial cells: implication of the sulfide oxidizing unit and of the cell respiratory capacity. Antioxid Redox Signal. 2012;17:1–10.CrossRefPubMed
10.
Motterlini R, Foresti R. Biological signaling by carbon monoxide and carbon monoxide-releasing molecules. Am J Physiol Cell Physiol. 2017;312:C302–C313.CrossRefPubMed
11.
Chang M, Xue J, Sharma V, Habtezion A. Protective role of hemeoxygenase-1 in gastrointestinal diseases. Cell Mol Life Sci. 2015;72:1161–1173.CrossRefPubMed
12.
Gibbons SJ, Verhurst PJ, Bharucha A, Farrugia G. Review article: carbon monoxide in gastrointestinal physiology and its potential in therapeutics. Aliment Pharmacol Ther. 2013;38:689–702.CrossRefPubMedPubMedCentral
13.
Farugia G, Szurszewski JH. Carbon monoxide, hydrogen sulfide, and nitric oxide as signaling molecules in the gastrointestinal tract. Gastroenterology. 2014;147:303–313.CrossRef
14.
Yoda Y, Amagase K, Kato S, et al. Prevention by lansoprazole, a proton pump inhibitor, of indomethacin-induced small intestinal ulceration in rats through induction of heme oxygenase-1. J Physiol Pharmacol. 2010;61:287–294.PubMed
15.
Brown JF, Hanson PJ, Whittle BJ. Nitric oxide donors increase mucus gel thickness in rat stomach. Eur J Pharmacol. 1992;223:103–104.CrossRefPubMed
16.
Price KJ, Hanson PJ, Whittle BJR. Stimulation by carbachol of mucus gel thickness in rat stomach involves nitric oxide. Eur J Pharmacol. 1994;263:199–202.CrossRefPubMed
17.
Lucetti LT, Silva RO, Santana AP, et al. Nitric oxide and hydrogen sulfide interact when modulating gastric physiological functions in rodents. Dig Dis Sci. 2017;62:93–104.CrossRefPubMed
18.
Costa NR, Silva RO, Nicolau LA, et al. Role of soluble guanylate cyclase activation in the gastroprotective effect of the HO-1/CO pathway against alendronate-induced gastric damage in rats. Eur J Pharmacol. 2013;700:51–59.CrossRefPubMed
19.
Motta JP, Flannigan KL, Agbor TA, et al. Hydrogen sulfide protects from colitis and restores intestinal microbiota biofilm and mucus production. Inflamm Bowel Dis. 2015;21:1006–1017.CrossRefPubMed
20.
Perdue MH, McKay DM. Integrative immunophysiology in the intestinal mucosa. Am J Physiol. 1994;267:G151–G165.PubMed
21.
MacNaughton WK. Nitric oxide-donating compounds stimulate electrolyte transport in the guinea pig intestine in vitro. Life Sci. 1993;53:585–593.CrossRefPubMed
22.
Tamai H, Gaginella TS. Direct evidence for nitric oxide stimulation of electrolyte secretion in the rat colon. Free Radic Res. 1993;19:229–239.CrossRef
23.
Asfaha S, MacNaughton WK, Appleyard CB, Chadee K, Wallace JL. Persistent epithelial dysfunction and bacterial translocation after resolution of intestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2001;281:G635–G644.PubMed
24.
Asfaha S, Bell CJ, Wallace JL, MacNaughton WK. Prolonged colonic epithelial hyperresponsiveness after colitis: role of inducible nitric oxide synthase. Am J Physiol. 1999;276:G703–G710.PubMed
25.
Takeuchi K, Aihara E, Kimura M, Dogishi K, Hara T, Hayashi S. Gas mediators involved in modulating duodenal HCO3 secretion. Curr Med Chem. 2012;19:43–54.CrossRefPubMed
26.
Takasuka H, Hayashi S, Koyama M, et al. Carbon monoxide involved in modulating HCO 3 - secretion in rat duodenum. J Pharmacol Exp Ther. 2011;337:293–300.CrossRefPubMed
27.
Takeuchi K, Kita K, Hayashi S, Aihara E. Regulatory mechanism of duodenal bicarbonate secretion: roles of endogenous prostaglandins and nitric oxide. Pharmacol Ther. 2011;130:59–70.CrossRefPubMed
28.
Blackler R, Syer S, Bolla M, Ongini E, Wallace JL. Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS ONE. 2012;7:e35196.CrossRefPubMedPubMedCentral
29.
Mard SA, Askari H, Neisi N, Veisi A. Antisecretory effect of hydrogen sulfide on gastric acid secretion and the involvement of nitric oxide. Biomed Res Int. 2014;2014:480921.CrossRefPubMedPubMedCentral
30.
Verdu E, Viani F, Armstrong D, et al. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut. 1994;35:455–460.CrossRefPubMedPubMedCentral
31.
Imhann F, Vich Vila A, Bonder MJ, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. 2017;24:1–8.CrossRef
32.
Keszthelyi D, Jansen SV, Schouten GA, et al. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther. 2010;32:1124–1128.CrossRefPubMed
33.
Shah R, Richardson P, Yu H, Kramer J, Hou JK. Gastric acid suppression is associated with an increased risk of adverse outcomes in inflammatory bowel disease. Digestion. 2017;95:188–193.CrossRefPubMed
34.
Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J Gastroenterol. 2015;21:6817–6819.PubMedPubMedCentral
35.
Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141:1314–1322.CrossRefPubMed
36.
Watanabe T, Tanigawa T, Nadatani Y, et al. Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage. Dig Liver Dis. 2013;45:390–395.CrossRefPubMed
37.
Washio E, Esaki M, Maehata Y, et al. Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: a randomized placebo-controlled trial. Clin Gastroenterol Hepatol. 2016;14:809–815.CrossRefPubMed
38.
Nuki Y, Umeno J, Washio E, et al. The influence of CYP2C19 polymorphisms on exacerbating effect of rabeprazole in celecoxib-induced small bowel injury. Aliment Pharmacol Ther. 2017. doi:10.​1111/​apt.​14134.PubMed
39.
Blackler RW, De Palma G, Manko A, et al. Deciphering the pathogenesis of NSAID enteropathy using proton pump inhibitors and a hydrogen sulfide-releasing NSAID. Am J Physiol Gastrointest Liver Physiol. 2015;308:G994–G1003.CrossRefPubMed
40.
Blackler RW, Motta JP, Manko A, et al. Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota. Br J Pharmacol. 2015;172:992–1004.CrossRefPubMed
41.
Kidder GW. Carbon monoxide insensitivity of gastric acid secretion. Am J Physiol. 1980;238:G197–G202.PubMed
42.
Pique JM, Esplugues JV, Whittle BJ. Endogenous nitric oxide as a mediator of gastric mucosal vasodilatation during acid secretion. Gastroenterology. 1992;102:168–174.CrossRefPubMed
43.
Holzer P, Sametz W. Gastric mucosal protection against ulcerogenicfactors in the rat mediated by capsaicin-sensitive afferent neurons. Gastroenterology. 1986;91:975–981.CrossRefPubMed
44.
45.
Lippe IT, Holzer P. Participation of endothelium-derived nitric oxide but not prostacyclin in the gastric mucosal hyperaemia due to acid back-diffusion. Br J Pharmacol. 1992;105:708–714.CrossRefPubMedPubMedCentral
46.
Fiorucci S, Antonelli T, Distrutti E, et al. Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory non-steroidal drugs. Gastroenterology. 2005;129:1210–1224.CrossRefPubMed
47.
Magierowska K, Magierowski M, Hubalewska-Mazgaj M, et al. Carbon monoxide (CO) released from tricarbonyldichlororuthenium (II) dimer (CORM-2) in gastroprotection against experimental ethanol-induced gastric damage. PLoS One. 2015;10:e0140493.CrossRefPubMedPubMedCentral
48.
Magierowski M, Magierowska K, Hubalewska-Mazgaj M, et al. Interaction between endogenous carbon monoxide and hydrogen sulfide in the mechanism of gastroprotection against acute aspirin-induced gastric damage. Pharmacol Res. 2016;114:235–250.CrossRefPubMed
49.
Banick PD, Chen QP, Xu YA, Thom SR. Nitric oxide inhibits neutrophil b2 integrin function by inhibiting membrane-associated cyclic GMP synthesis. J Cell Physiol. 1997;172:12–24.CrossRefPubMed
50.
Davenpeck KL, Gauthier TW, Lefer AM. Inhibition of endothelial derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation. Gastroenterology. 1994;107:1050–1058.CrossRefPubMed
51.
52.
Wallace JL, Vergnolle N, Muscara MN, et al. Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. Gastroenterology. 1999;117:557–566.CrossRefPubMed
53.
Zanardo RC, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, Wallace JL. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J. 2006;20:2118–2120.CrossRefPubMed
54.
Wallace JL, Caliendo G, Santagada V, Cirino G. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol. 2010;159:1236–1246.CrossRefPubMedPubMedCentral
55.
Urquhart P, Rosignoli G, Cooper D, Motterlini R, Perretti M. Carbon monoxide-releasing molecules modulate leukocyte-endothelial interactions under flow. J Pharmacol Exp Ther. 2007;321:656–662.CrossRefPubMed
56.
Paul G, Bataille F, Obermeier F, et al. Analysis of intestinal haem-oxygenase-1 (HO-1) in clinical and experimental colitis. Clin Exp Immunol. 2005;140:547–555.CrossRefPubMedPubMedCentral
57.
Tepperman BL, Soper BD. Nitric oxide synthase induction and cytoprotection of rat gastric mucosa from injury by ethanol. Can J Physiol Pharmacol. 1994;72:1308–1312.CrossRefPubMed
58.
Motterlini R, Foresti R, Intaglietta M, Winslow RM. NO-mediated activation of heme oxygenase: endogenous cytoprotection against oxidative stress to endothelium. Am J Physiol. 1996;270:H107–H114.PubMed
59.
Lohmander LS, McKeith D, Svensson O, et al. Ramos-Remus C; STAR Multinational Study Group. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis. 2005;64:449–456.CrossRefPubMed
60.
Wallace JL. Physiological and pathophysiological roles of hydrogen sulfide in the gastrointestinal tract. Antioxid Redox Signal. 2010;12:1125–1133.CrossRefPubMed
61.
Wallace JL, Vaughan D, Dicay M, MacNaughton WK, de Nucci G. Hydrogen sulfide-releasing therapeutics: Translation to the clinic. Antiox Redox Signal 2017; in press (doi: 10.​1089/​ars.​2017.​7068).
62.
Uc A, Zhu X, Wagner BA, Guettner GR, Berg DJ. Heme oxygenase-1 is protective against nonsteroidal anti-inflammatory drug-induced gastric ulcers. J Ped Gastroenterol Nutr. 2012;54:471–476.CrossRef
63.
Cheng Y-T, Wu C-H, Ho C-Y, Yen G-C. Catechin protects against ketoprofen-induced oxidative damage of the gastric mucosa by up-regulating Nrf2 in vitro and in vivo. J Nutr Biochem. 2013;24:475–483.CrossRefPubMed
64.
De Backer O, Elinck E, Blanckaert B, Leybaert L, Motterlini R, Lefebvre RA. Water-soluble CO-releasing molecules reduce the development of postoperative ileus via modulation of MAPK/HO-1 signalling and reduction of oxidative stress. Gut. 2009;58:347–356.CrossRefPubMed
65.
Konturek SJ, Brzozowski T, Majka J, Pytko-Polonczyk J, Stachura J. Inhibition of nitric oxide synthase delays healing of chronic gastric ulcers. Eur J Pharmacol. 1993;239:215–217.CrossRefPubMed
66.
Elliott SN, McKnight W, Cirino G, Wallace JL. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology. 1995;109:524–530.CrossRefPubMed
67.
Wallace JL, Dicay M, McKnight W, Martin GR. Hydrogen sulfide enhances ulcer healing in rats. FASEB J. 2007;21:4070–4076.CrossRefPubMed
68.
Wallace JL, Vong L, McKnight W, Dicay M, Martin GR. Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats. Gastroenterology. 2009;137:569–578.CrossRefPubMed
69.
Flannigan KL, Ferraz JGP, Wang R, Wallace JL. Enhanced synthesis and diminished degradation of hydrogen sulfide in experimental colitis: A site-specific, pro-resolution mechanism. PLoS One. 2013;8:e71962.CrossRefPubMedPubMedCentral
70.
Takagi T, Naito Y, Uchiyama K, et al. Carbon monoxide promotes gastric wound healing in mice via the protein kinase C pathway. Free Radic Res. 2016;50:1098–1105.CrossRefPubMed
71.
Schaffer MR, Tantry U, Gross SS, Wasserkrug HL, Barbul A. Nitric oxide regulates wound healing. J Surg Res. 1996;63:237–240.CrossRefPubMed
72.
Hirose H, Takeuchi K, Okabe S. Effect of indomethacin on gastric mucosal blood flow around acetic acid–induced gastric ulcers in rats. Gastroenterology. 1991;100:1259–1265.CrossRefPubMed
73.
Papapetropoulos A, Foresti R, Ferdiandy P. Pharmacology of the ‘gasotransmitters’ NO, CO and H2S: translational opportunities. Br J Pharmacol. 2015;172:1395–1396.CrossRefPubMedPubMedCentral
74.
Flannigan KL, Agbor TA, Blackler RW, et al. Impaired hydrogen sulfide synthesis and IL-10 signaling underlie hyperhomocysteinemia-associated exacerbation of colitis. Proc Natl Acad Sci USA. 2014;111:13559–13564.CrossRefPubMedPubMedCentral
75.
Lagoutte E, Mimoun S, Andriamihaja M, et al. Oxidation of hydrogen sulfide remains a priority in mammalian cells and causes reverse electron transfer in colonocytes. Biochim Biophys Acta. 2010;1797:1500–1511.CrossRefPubMed
76.
Shen X, Carlström M, Borniquel S, Jädert C, Kevil CG, Lundberg JO. Microbial regulation of host hydrogen sulfide bioavailability and metabolism. Free Radic Biol Med. 2013;60:195–200.CrossRefPubMedPubMedCentral
77.
Flannigan KL, McCoy KD, Wallace JL. Eukaryotic and prokaryotic contributions to colonic hydrogen sulfide synthesis. Am J Physiol Gastrointest Liver Physiol. 2011;301:G188–G193.CrossRefPubMed
78.
Lund JN, Scholefield JH. Glyceryl trinitrate is an effective treatment for anal fissure. Dis Colon Rectum. 1997;40:468–470.CrossRefPubMed
79.
Hogaboam CM, Jacobson K, Collins SM, Blennerhassett MG. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am J Physiol. 1995;268:G673–G684.PubMed
80.
Aiko S, Fuseler J, Grisham MB. Effects of nitric oxide synthase inhibition or sulfasalazine on the spontaneous colitis observed in HLA-B27 transgenic rats. J Pharmacol Exp Ther. 1998;284:722–727.PubMed
81.
Soufli I, Toumi R, Rafa H, Touil-Boukoffa C. Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases. World J Gastrointest Pharmacol Ther. 2016;7:353–360.CrossRefPubMedPubMedCentral
82.
McCafferty DM, Mudgett JS, Swain MG, Kubes P. Inducible nitric oxide synthase plays a critical role in resolving intestinal inflammation. Gastroenterology. 1997;112:1022–1027.CrossRefPubMed
83.
Takagi T, Naito Y, Uchiyama K, et al. Carbon monoxide liberated from carbon monoxide-releasing molecule exerts an anti-inflammatory effect on dextran sulfate sodium-induced colitis in mice. Dig Dis Sci. 2011;56:1663–1671.CrossRefPubMed
84.
Uddin MJ, Jeong SO, Zheng M, et al. Carbon monoxide attenuates dextran sulfate sodium-induced colitis via inhibition of GSK-3ß signaling. Oxid Med Cell Longev. 2013;2013:210563.CrossRefPubMedPubMedCentral
85.
Megias J, Busserolles J, Alcaraz MJ. The carbon monoxide-releasing molecule CORM-2 inhibits the inflammatory response induced by cytokines in Caco-2 cells. Br J Pharmacol. 2007;150:977–986.CrossRefPubMedPubMedCentral
86.
Onyiah JC, Sheikh SZ, Maharshak N, Otterbein LE, Plevy SE. Heme oxygenase-1 and carbon monoxide regulate intestinal homeostasis and mucosal immune responses to the enteric microbiota. Gut Microbes. 2014;5:220–224.CrossRefPubMed
87.
Szczesny B, Módis K, Yanagi K, et al. AP39, a novel mitochondria-targeted hydrogen sulfide donor, stimulates cellular bioenergetics, exerts cytoprotective effects and protects against the loss of mitochondrial DNA integrity in oxidatively stressed endothelial cells in vitro. Nitric Oxide. 2014;41:120–130.CrossRefPubMedPubMedCentral
88.
Shibuya N, Koike S, Tanaka M, et al. A novel pathway for the production of hydrogen sulfide from d-cysteine in mammalian cells. Nat Commun. 2013;4:1366.CrossRefPubMed
89.
Wallace JL, Blackler RW, Chan MV, et al. Anti-inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics. Antiox Redox Signal. 2015;22:398–410.CrossRef
Metadata
Title
Gaseous Mediators in Gastrointestinal Mucosal Defense and Injury
Authors
John L. Wallace
Angela Ianaro
Gilberto de Nucci
Publication date
01-09-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 9/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4681-0

Other articles of this Issue 9/2017

Digestive Diseases and Sciences 9/2017 Go to the issue

Original Article

Regional Variability of Repeat Esophagogastroduodenoscopy Use in the National Veteran Population

Original Article

High Center Volume Does Not Mitigate Risk Associated with Using High Donor Risk Organs in Liver Transplantation

Original Article

Latiglutenase Improves Symptoms in Seropositive Celiac Disease Patients While on a Gluten-Free Diet

Original Article

Comparison of 4-L Polyethylene Glycol and 2-L Polyethylene Glycol Plus Ascorbic Acid in Patients with Inactive Ulcerative Colitis

Correspondence

Does Metabolic Syndrome and Not the Inflammatory Load Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients?

Original Article

Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits